Ontology highlight
ABSTRACT:
SUBMITTER: Arrieta VA
PROVIDER: S-EPMC8818262 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
Arrieta Víctor A VA Chen Andrew X AX Kane J Robert JR Kang Seong Jae SJ Kassab Cynthia C Dmello Crismita C Zhao Junfei J Burdett Kirsten B KB Upadhyayula Pavan S PS Lee-Chang Catalina C Shilati Joseph J Jaishankar Dinesh D Chen Li L Gould Andrew A Zhang Daniel D Yuan Jinzhou J Zhao Wenting W Ling Xiaoyang X Burks Jared K JK Laffleur Brice B Amidei Christina C Bruce Jeffrey N JN Lukas Rimas V RV Yamaguchi Jonathan T JT Cieremans David D Rothschild Gerson G Basu Uttiya U McCord Matthew M Brat Daniel J DJ Zhang Hui H Cooper Lee A D LAD Zhang Bin B Sims Peter P Cloughesy Tim F TF Prins Robert R Canoll Peter P Stupp Roger R Heimberger Amy B AB Horbinski Craig C Iwamoto Fabio M FM Rabadan Raul R Sonabend Adam M AM
Nature cancer 20211129 12
Only a subset of recurrent glioblastoma (rGBM) responds to anti-PD-1 immunotherapy. Previously, we reported enrichment of BRAF/PTPN11 mutations in 30% of rGBM that responded to PD-1 blockade. Given that BRAF and PTPN11 promote MAPK/ERK signaling, we investigated whether activation of this pathway is associated with response to PD-1 inhibitors in rGBM, including patients that do not harbor BRAF/PTPN11 mutations. Here we show that immunohistochemistry for ERK1/2 phosphorylation (p-ERK), a marker o ...[more]